Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 18Radiotherapy 10Cisplatin 10Pemetrexed 8Paclitaxel 8durvalumab 6Magnetic Resonance Spectroscopy 6Gemcitabine 6Radiosurgery 5Nivolumab 5Etoposide 5pembrolizumab 4atezolizumab 4Surveys and Questionnaires 4Radiation 4Erlotinib Hydrochloride 4Docetaxel 4Taxes 3Standard of Care 3Specimen Handling 3Platinum 3Cetuximab 3Bronchoscopy 3Biopsy 3Bevacizumab 31,2-diaminocyclohexaneplatinum II citrate 3sapanisertib 2etoposide phosphate 2capmatinib 2Vinorelbine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Lung Neoplasms × Congresses as Topic × Clear all
NCT04989283 2023-09-26

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Withdrawn
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡